These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 21730794

  • 1. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H.
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A.
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [Abstract] [Full Text] [Related]

  • 3. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS.
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
    Noda E, Maeda K, Inoue T, Fukunaga S, Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K, Yamada N, Yashiro M, Ohira M, Ishikawa T, Hirakawa K.
    Hepatogastroenterology; 2012 Oct; 59(113):130-3. PubMed ID: 21940361
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 6. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
    Alexander HR, Grem JL, Hamilton JM, Pass HI, Hong M, Fraker DL, Steinberg SM, McAtee N, Allegra BC, Johnston PG.
    Cancer J Sci Am; 1995 Feb; 1(1):49-54. PubMed ID: 9166454
    [Abstract] [Full Text] [Related]

  • 7. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
    Ren DN, Kim IY, Koh SB, Chang SJ, Eom M, Yi SY, Seong SH, Kim MD, Bronner MP, Cho MY.
    J Surg Oncol; 2009 Dec 01; 100(7):546-52. PubMed ID: 19722231
    [Abstract] [Full Text] [Related]

  • 8. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
    Xi Y, Formentini A, Nakajima G, Kornmann M, Ju J.
    Oncol Rep; 2008 Jan 01; 19(1):257-62. PubMed ID: 18097604
    [Abstract] [Full Text] [Related]

  • 9. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC, Yun SH, Chun HK.
    Anticancer Res; 2011 Nov 01; 31(11):3843-9. PubMed ID: 22110208
    [Abstract] [Full Text] [Related]

  • 10. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ.
    PLoS One; 2013 Nov 01; 8(7):e66774. PubMed ID: 23861747
    [Abstract] [Full Text] [Related]

  • 11. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.
    Oncology; 2006 Nov 01; 70(5):366-77. PubMed ID: 17179731
    [Abstract] [Full Text] [Related]

  • 12. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M.
    Cancer Biomark; 2009 Nov 01; 5(4):167-75. PubMed ID: 19729826
    [Abstract] [Full Text] [Related]

  • 13. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y, Inoue Y, Saigusa S, Okugawa Y, Yokoe T, Tanaka K, Miki C, Kusunoki M.
    Clin Oncol (R Coll Radiol); 2010 May 01; 22(4):272-80. PubMed ID: 20117921
    [Abstract] [Full Text] [Related]

  • 14. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
    Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A, Ladner RD, Zhang W, Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz HJ.
    Pharmacogenomics J; 2013 Oct 01; 13(5):410-6. PubMed ID: 22664478
    [Abstract] [Full Text] [Related]

  • 15. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M, Hoshino S, Noda N, Nakano M, Matsuo K, Yamauchi Y, Shinohara T, Tanaka S, Yamashita Y.
    Gan To Kagaku Ryoho; 2010 Jan 01; 37(1):83-8. PubMed ID: 20087037
    [Abstract] [Full Text] [Related]

  • 16. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S.
    J Clin Oncol; 2005 Jun 01; 23(16):3706-12. PubMed ID: 15867200
    [Abstract] [Full Text] [Related]

  • 17. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
    Koyama M, Murata A, Kimura Y, Sakamoto Y, Morohashi H, Kimura N, Gasa F, Sato J, Terui K, Awatsu A, Hakamada K.
    Gan To Kagaku Ryoho; 2010 Jun 01; 37(6):1069-73. PubMed ID: 20567110
    [Abstract] [Full Text] [Related]

  • 18. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
    Yamada H, Ichikawa W, Uetake H, Shirota Y, Nihei Z, Sugihara K, Hirayama R.
    Clin Colorectal Cancer; 2001 Nov 01; 1(3):169-73; discussion 174. PubMed ID: 12450430
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G.
    Ann Oncol; 2006 Jan 01; 17(1):35-42. PubMed ID: 16251201
    [Abstract] [Full Text] [Related]

  • 20. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH, Jensen BV, Larsen FO.
    Acta Oncol; 2010 Apr 01; 49(3):395-6. PubMed ID: 20001495
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.